Kalydeco 75 mg

KALYDECO 75 MG granules contain ivacaftor, a medication used to treat certain genetic conditions. This oral therapy is designed for specific cystic fibrosis mutations, offering targeted support for respiratory health.

KALYDECO 75 MG granules are primarily used in the management of cystic fibrosis in patients with specific genetic mutations. Ivacaftor, the active ingredient, works to improve the function of a protein affected by these mutations, aiming to enhance respiratory health. This medication is often prescribed as part of a broader treatment plan for cystic fibrosis, focusing on maintaining lung function and overall well-being.

Common effects of KALYDECO 75 MG granules may include improvements in lung function and respiratory symptoms. Some individuals might experience side effects such as headaches, stomach discomfort, or dizziness. It's important to monitor any changes in health and consult a healthcare provider if concerns arise.

KALYDECO 75 MG granules should be handled with care, ensuring proper storage and administration as directed. Patients should inform their healthcare provider about any existing medical conditions or other medications they are taking. Regular monitoring and follow-up are recommended to ensure the medication's effectiveness and safety.

KALYDECO 75 MG granules may interact with certain medications, including those metabolized by the liver's CYP3A4 enzyme. It's important to avoid grapefruit and grapefruit juice, as they can affect the metabolism of ivacaftor. Always consult a healthcare provider before starting or stopping any medication while using KALYDECO.